Halozyme Reports Roche Granted EU Clearance for Subcutaneous Form of Tecentriq® with ENHANZE® Technology, Marking a Breakthrough in the Delivery of Immunotherapies Across Various Cancers.

On Jan 17, 2024, Windtree Therapeutics announced a licensing deal with Lee's Pharm for its heart failure drug istaroxime in Greater China.

Chipscreen NewWay Initiates Phase 1 Study: Administers Initial Dose of Innovative Dual-Targeting Antibody NWY001 for Advancing Cancer Immune Therapy in Individuals with Progressive Solid Cancers.

The ClinicalTrials.gov database provides information about clinical trials that are currently recruiting or have recently been completed.

InnoCare Pharma has disclosed that the FDA has given approval to proceed with the clinical study for its BCL2 inhibitor, designated as ICP-248.

On January 8, 2024, Johnson & Johnson acquired Ambrx Biopharma for $2 billion to enhance its Antibody-Drug Conjugate (ADC) portfolio, including promising treatments like ARX517 for metastatic prostate cancer.

AM-Pharma B.V. has started Phase 2 trials treating patients to test its enzyme, ilofotase alfa, for preventing kidney injury post-cardiac surgery.

ClinicalTrials.gov is a public database that contains information on clinical trials conducted around the world.

ExeVir Bio reports its antibodies effectively neutralize current COVID-19 Omicron strains.

Hope Medicine Inc. announces successful completion of its Phase Ib "An Open-Label Study on Safety and Efficacy of HMI-115 in Androgenetic Alopecia over 24 Weeks," advancing its research milestones.

Indapta Therapeutics Reveals Initial Treatment of Patients Using IDP-023, a Non-Self Derived NK Cell Treatment for Cancer Management.

PharmaLogic Holdings Corp. has struck a deal with clinical stage innovator ARTBIO for the production of AB001, an experimental prostate cancer treatment using lead-212.